One of the most persistent frustrations in oncology is that even the best immune checkpoint therapies fail in a substantial fraction of patients — and the reasons why remain incompletely understood. New mechanistic work published in Immunity identifies a previously underappreciated axis through which the immune system actively undermines its own anti-tumor response: neutrophils, instructed by interferon-gamma, can be converted into potent brakes on immunotherapy efficacy.
Working with neutropenic mouse models, investigators demonstrated that the dominant net function of neutrophils in the context of T-cell- or myeloid-targeted immunotherapies is suppressive. The team traced the mechanism to upregulation of PD-L1 (encoded by cd274) on neutrophil surfaces — not as a baseline feature, but as a direct treatment-induced response. Crucially, this PD-L1 upregulation was driven by interferon-gamma (IFN-γ) secreted by cytotoxic lymphocytes — the very effector cells immunotherapy is meant to activate. Cell-intrinsic validation via conditional deletion of either cd274 or the IFN-γ receptor gene Ifngr1 specifically in neutrophils confirmed the pathway is autonomous to that population. Strikingly, neutrophils lacking this IFN-γ-signaling capacity did not simply become neutral; they shifted phenotypically to actively support immunotherapy.
This finding reframes a longstanding puzzle about tumor-associated neutrophils, which have long been recognized as functionally heterogeneous but poorly characterized mechanistically. The work places IFN-γ — the canonical pro-inflammatory cytokine and a cornerstone of anti-tumor immunity — at the center of a paradoxical immunosuppressive feedback loop. This is conceptually significant: the therapeutic activation of cytotoxic lymphocytes simultaneously generates a suppressive neutrophil signal via IFN-γ, creating an intrinsic resistance mechanism. The data are preclinical and mouse-derived, so translation to human tumor microenvironments requires validation. Nonetheless, this circuit suggests that neutrophil PD-L1 depletion strategies or Ifngr1 blockade selectively in myeloid populations could meaningfully expand immunotherapy responder rates — an incremental but mechanistically clarifying step in the resistance biology field.